Rubius Therapeutics Property, Plant & Equipment

Rubius Therapeutics (RUBY) currently reports a PP&E of $2.8M as of December 2022. That compares with $87M in the prior-year period — down 96.7% year over year. Use the charts on this page to explore Rubius Therapeutics's PP&E history and peer comparisons.

Rubius Therapeutics's PP&E decreased from $87M to $2.8M — a 96.7% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rubius Therapeutics reported $2.8M in PP&E as of December 2022. That compares with $87M in the prior-year period — down 96.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current PP&E of $2.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Rubius Therapeutics, and consider following RUBY for alerts when major investors trade the stock.

Rubius Therapeutics is classified in the Healthcare sector. On PP&E, it currently shows $2.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RUBY with unrelated industries.